6-K
Evotec SE (EVO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2025
COMMISSION FILE NUMBER 001-34041
Evotec SE
(Translation of registrant’s name into English)
Essener Bogen 7
22419 Hamburg
Germany
Tel: +49 40 560810
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On December 08, 2025, Evotec SE (the “Company”) issued a press release announcing closing of agreement with Sandoz attached as Exhibit 99.1 hereto.
EXHIBIT INDEX
| Exhibit | Description of Exhibit |
|---|---|
| 99.1 | Evotec closes sale of Just – Evotec Biologics’ Toulouse site<br> to Sandoz |
SIGNATURE
Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Evotec SE | |
|---|---|
| By: | /s/ Christian Wojczewski |
| Name:<br> Christian Wojczewski | |
| Title: Chief Executive Officer |
Date: December 08, 2025
Exhibit 99.1
Evotec closes sale of Just– Evotec Biologics’ Toulouse site to Sandoz
| • | All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November |
|---|---|
| • | Agreement includes approximately US$ 350 m in cash for Just – Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec’s continuous manufacturing platform |
| • | In addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years, replacing existing contractual commitments |
| • | Transaction covering royalties on a portfolio of up to ten biosimilars in technical and early development targeting more than US$ 90 bn of originator net sales |
| • | Sale immediately earnings accretive, improving Evotec’s short, mid and long-term revenue mix, profit margins, and capital efficiency |
Hamburg, Germany, 08 December2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced the closing of its previously reported sale of the Just – Evotec Biologics Toulouse site plus an indefinite technology license to Evotec’s continuous manufacturing platform technology to Sandoz AG (SIX: SDZ / OTCQX: SDZNY), effective 05 December 2025. In total, potential payments may exceed US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules, of which six have an originator net sales value of US$ 90 bn.
The transaction with Sandoz is accelerating the implementation of Evotec’s strategy through better monetization of its technology and transitioning to an asset-lighter business model. Evotec is delivering on sharpening its focus on its core strengths and is well on track for sustainable and profitable growth. Sandoz’s acquisition of Just – Evotec Biologics’ Toulouse site is an endorsement of the pioneering J.POD platform and its potential to revolutionize biologics manufacturing.
Dr Christian Wojczewski,Chief Executive Officer of Evotec, said: “This transaction is a pivotal step in Evotec’s transition to a scalable technology provider for next-generation biologics development. By selling the Just – Evotec Biologics Toulouse site and a license for using our pioneering continuous manufacturing technology to Sandoz, we are not only unlocking significant value today but also paving the way for a more efficient, sustainable, and accessible future for biologic medicines.“
Page 1 of 2
With the closing of the transaction, Evotec will continue to serve its customers in the U.S. and Europe with capacity for molecular design, upstream, downstream, analytical and formulation development as well as first-in-human to commercial biologics GMP manufacturing. In parallel, Evotec plans to enable its partners to lower the time and costs of biologics manufacturing with its paradigm shifting continuous manufacturing technology and assets beyond its own capacity via a technology license model.
About Evotec SE
Evotec is a life sciencecompany that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovationand advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.
Our expertise spans smallmolecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases,PanOmics and iPSC-based disease modeling.
With flexible partneringmodels tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, andhealthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships,combining scientific excellence with operational agility.
Through Just – EvotecBiologics, we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolioof over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascularand metabolic diseases, neurology, and immunology.
Evotec’s global teamof more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergisticcenters of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.
Forward-looking statements
This announcement containsforward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Wordssuch as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”“may,” “might,” “plan,” “potential,” “should,” “target,” “would”and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include commentsregarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements arebased on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statementswere made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknownrisks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies,many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updatesor revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect theretoor any change in events, conditions or circumstances on which any statement is based.
For further information,please contact:
Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com
Investor Relations
Volker Braun
EVP Head of Global InvestorRelations & ESG
Volker.Braun@evotec.com
Page 2 of 2